Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Werewolf Therapeutics, Inc. (HOWL)

Werewolf sells preclinical platforms to EMD Serono for $28.0 million upfront

Neutral Impact 3 of 5 m&a Written later

On August 14, 2026, Werewolf Therapeutics agreed to sell its pre-clinical INDUCER and INDUKINE platform technology to EMD Serono, with EMD paying $28.0 million upfront and an additional $5.0 million upon completion of the technology transfer. The company keeps its WTX-124 and WTX-330 clinical programs and received an exclusive license to certain patents needed to develop them, but it agreed to a 24-month non-competition covenant on certain related compounds.

Key points

  • Upfront consideration of $28.0 million, plus an additional $5.0 million upon completion of the technology transfer
  • Sold INDUCER and INDUKINE pre-clinical platforms and related compounds, excluding the WTX-124 and WTX-330 clinical programs
  • Company retains rights to continue developing WTX-124 and WTX-330
  • Non-competition covenant for 24 months after closing, with customary exceptions for change of control transactions

The filing

CompanyWerewolf Therapeutics, Inc. (HOWL)
Form8-K, current report
Filed with the SECAug 20, 2026, 4:06 PM ET
Accession number0001193125-26-359185

Items reported: 1.01 Material Definitive Agreement

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 20, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.